A novel dengue vaccine candidate that induces cross-neutralizing antibodies and memory immunity

Evaluation of protective efficacy using a nonstructural protein NS1 in DNA vaccine–loaded microspheres against dengue 2 virus

“…[3][4][5] There are four serotypes of dengue virus (DEN1-DEN4) that are endemic in most areas of Southeast Asia, Central and South America, and other subtropical regions. 6 Illnesses range from inapparent infection to dengue fever, or, in severe cases, potentially fatal dengue hemorrhagic fever/dengue shock syndrome.…”

“…Recent advances in recombinant deoxyribonucleic acid (DNA) technology have made it possible to explore a novel approach for developing vaccines. 4 Natural infection or vaccination with native and recombinant proteins may induce an immune response to the surface envelope E-protein, which has been shown to be protective to superinfection with homologous serotype of the virus.…”

Dengue vaccine: an update on recombinant subunit strategies

“…Th e lipid moiety of the recombinant lipoprotein contains a ligand for toll-like receptor 2 (Leng et al, 2010), that provides the proteins with self-adjuvanting properties. Th e cED III formulated with aluminum phosphate (20 μg per dose given three times at two-week intervals) induced neutralizing antibodies against the four DV serotypes in mice (Leng et al, 2009), but only DV2-specifi c neutralizing antibodies in two of three immunized monkeys (Chen et al, 2013). Th e lipidated consensus dengue virus E protein domain III activated macrophages and up-regulated the expression of CD40, MHC II, and co-stimulatory molecules in vitro (Chiang et al, 2011).…”

“…Tetravalent candidate evaluated in mice; monovalent DV1 and DV2 candidates evaluated in NHPs Hermida et al, 2006;Lazo et al, 2014;Valdés et al, 2009a] EDIII-capsid fusion protein (DIIIC) expressed in E. coli Monovalent DV2 candidate evaluated in NHPs [Gil et al, 2015;Suzarte et al, 2014;Valdés et al, 2009b;Zuest et al, 2015] Tetravalent EDIII-STF2 fusion proteins expressed in E. coli Tetravalent candidate evaluated in mice and NHPs [Liu et al, 2015] EDIII-HBcAg fusion protein expressed in P. pastoris Monovalent DV2 candidate evaluated in mice Recombinant EDII-EDIII-NS1 fusion protein expressed in Drosophila S2 Tetravalent lipidated consensus EDIII (LcED III) expressed in E. coli Tetravalent candidate evaluated in mice [Chen et al, 2013;Chiang et al, 2011;Leng et al, 2009] Lipidated EDIII (LED III) expressed in E. coli Monovalent candidates (DV1,2,4) evaluated in mice [Chiang et al, 2011[Chiang et al, , 2013a MixBiEDIII: bivalent EDIIIs (DV1-2/ DV3-4) expressed in E. coli Tetravalent candidate evaluated in mice [Zhao et al, 2014] Bivalent EDIII (DV1-2) expressed in E. coli Bivalent candidate (DV1-2) evaluated in mice [Zhang et al, 2015] Tetravalent chimeric EDIII expressed in P. pastoris Tetravalent candidate evaluated in mice [Etemad et al, 2008] Non-structural proteins Recombinant DV2 NS1 protein expressed in E. coli Monovalent DV2 candidate evaluated in mice [Amorim et al, 2012] Recombinant DV2 NS1-DEC205 fusion protein expressed in E. coli Monovalent DV2 candidate evaluated in mice [Henriques et al, 2013] Full-length recombinant DV2 NS3 protein expressed in E. coli Monovalent DV2 candidate evaluated in mice [Ramírez et al, 2014] Capsid protein Recombinant capsid protein expressed in E. coli Monovalent DV2 candidate evaluated in mice and NHPs …”

Vaccines for the prevention of dengue: Development update

“…Most recently, scientists have been developing candidates targeting Domain III of the DENV E protein (EDIII), exploring use of various DENV antigen/adjuvant combinations, antigen expression and vector delivery systems and assessing the immunogenicity of heterologous prime/ boost vaccination strategies. [106][107][108][109][110][111][112][113][114][115][116][117][118][119][120][121][122][123] DENVs naturally infect non-human primates (NHPs) and support a sylvatic transmission cycle. 124 All DENV types can infect and replicate in NHPs without adaptation, producing 3 to 7 days of viremia and a robust neutralizing antibody response.…”